僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Benralizumab （MEDI-563） is an interleukin-5 receptor α （IL-5Rα）-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma